摘要
严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 感染一直是全球性挑战。 2019 年冠状病毒病 (COVID-19) 的复杂形式可演变为多器官衰竭,包括与呼吸状况突然恶化相关的几种凝血病。本文旨在回顾与 COVID-19 直接相关的血液学和止血实验室疾病的研究,并讨论 SARS-CoV-2 如何导致这些异常。凝血级联模型与 COVID-19 和肺部受累有关。实验室变化与评估凝血状态相关 - D-二聚体、凝血酶原时间 (PT)、活化部分凝血活酶时间 (APTT)、血小板计数和纤维蛋白原。孕妇和体外膜氧合 (ECMO) 患者需要特别注意。 COVID-19 凝血病的预防性干预措施应考虑有血栓事件风险和潜在禁忌症的患者。 SARS-CoV-2 损害止血平衡的机制包括内皮损伤、炎症以及免疫和补体系统的激活。对于凝血功能障碍的诊断,应在 COVID-19 患者中评估主要是 D-二聚体,但也包括 PT、APTT 和 FDP。低分子量肝素 (LMWH) 和普通肝素 (UFH) 之间的干预可能性各不相同。到目前为止,有足够的证据表明,有凝血病危险因素的急性病患者在住院期间和出院后可从血栓预防中获益,但并非所有患者。
关键词: COVID-19、凝血、凝血病、急性呼吸窘迫综合征、血管紧张素转换酶 2、SARS-CoV-2。
Current Medicinal Chemistry
Title:COVID-19 Related Coagulopathy: What is Known Up to Now
Volume: 28 Issue: 21
关键词: COVID-19、凝血、凝血病、急性呼吸窘迫综合征、血管紧张素转换酶 2、SARS-CoV-2。
摘要: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has been a global challenge. The complicated forms of the Coronavirus Disease 2019 (COVID- 19) can evolve to multiple-organ failure, including several coagulopathies related to a sudden worsening of respiratory status. This article aimed to review studies about hematological and hemostatic laboratory disorders directly related to COVID-19 and to discuss how SARS-CoV- 2 causes these abnormalities. The coagulation cascade model is associated with both COVID- 19 and pulmonary involvement. Laboratory changes are relevant to evaluate the coagulation state - D-dimer, prothrombin time (PT), Activated Partial Thromboplastin Time (APTT), platelet count and fibrinogen. Pregnant women and patients in Extracorporeal Membrane Oxygenation (ECMO) need special attention. Prophylactic interventions for COVID-19 coagulopathy should consider patients at risk for thrombotic events and potential contraindications. The mechanisms exerted by SARS-CoV-2 that impairs hemostatic balance include endothelial injury, inflammation, and activation of the immune and complement systems. For diagnosis of coagulopathy, mainly D-dimer, but also PT, APTT and FDP, should be evaluated in COVID-19 patients. Intervention possibilities vary between low-molecular-weight heparin (LMWH) and Unfractionated Heparin (UFH). Until now, there is sufficient evidence that acutely-ill patients with risk factors for coagulopathies will benefit from thrombophylaxis during hospitalization and post-discharge, but not all patients.
Export Options
About this article
Cite this article as:
COVID-19 Related Coagulopathy: What is Known Up to Now, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867327666201005112231
DOI https://dx.doi.org/10.2174/0929867327666201005112231 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Recent Patents Regarding Essential Oils and the Significance of their Constituents in Human Health and Treatment
Recent Patents on Anti-Infective Drug Discovery Modern Treatment of Infection and Ischaemia to Reduce Major Amputation in the Diabetic Foot
Current Pharmaceutical Design Statins as Either Immunomodulators or Anti-Cancer Drugs: Functional Activities on Tumor Stromal Cells and Natural Killer Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry Optical Chemical Biosensors for High Throughput Screening of Drugs
Combinatorial Chemistry & High Throughput Screening Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Anti-inflammatory, Antioxidant, Lung and Liver Protective Activity of <i>Galaxaura oblongata</i> as Antagonistic Efficacy against LPS using Hematological Parameters and Immunohistochemistry as Biomarkers
Cardiovascular & Hematological Agents in Medicinal Chemistry Mentha L. Species (Lamiaceae) as Promising Sources of Bioactive Secondary Metabolites
Current Pharmaceutical Design Novel Strategies for the Detection of Systolic and Diastolic Heart Failure
Current Cardiology Reviews Influence of Dietary Substances on Intestinal Drug Metabolism and Transport
Current Drug Metabolism Leeches: Immune Response, Angiogenesis and Biomedical Applications
Current Pharmaceutical Design Medicinal Chemistry and Anti-Inflammatory Activity of Nitric Oxide-Releasing NSAI Drugs
Mini-Reviews in Medicinal Chemistry Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives
Current Pharmaceutical Design Anthocyanins as a Potential Therapy for Diabetic Retinopathy
Current Medicinal Chemistry Probiotics as an Alternative Strategy for Prevention and Treatment of Human Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) miR-122 is a Unique Molecule with Great Potential in Diagnosis, Prognosis of Liver Disease, and Therapy Both as miRNA Mimic and Antimir
Current Gene Therapy Recent Advances in the Development of Small-molecule CCR5 Inhibitors for HIV
Mini-Reviews in Medicinal Chemistry Determinants of Smoking Cessation Attempts Among HIV-Infected Patients: Results from a Hospital-Based Prospective Cohort
Current HIV Research Herbal Highs: Review on Psychoactive Effects and Neuropharmacology
Current Neuropharmacology